Brian S. Posner
Director
Common Stock
- Reported value
- $40K
- Reported price
- $16.00 / share
Dyne Therapeutics, Inc.
Last 30 daysInsiders bought $40K · 1 buyer, led by Brian S. Posner (Director) with $40K. Sales: $247.78K by 3 insiders.
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Excluded from the common-share buying signal. See trade details.
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Director | Common StockPurchase | 2,500$16.00 / share | $40K | Oct 2Filed Oct 6 · 4d later | SEC filing |
| Director | Common StockPurchase | 2,000$16.94 / share | $33.88K | Jun 8Filed Jun 9 · 1d later | SEC filing |
| Director | Common StockPurchase | 2,500$17.48 / share | $43.7K | Jun 3Filed Jun 5 · 2d later | SEC filing |
| Director | Common StockPurchase | 2,000$18.21 / share | $36.42K | May 26Filed May 28 · 2d later | SEC filing |
| Director | Common StockPurchase | 2,500$17.12 / share | $42.8K | May 20Filed May 22 · 2d later | SEC filing |
| Director | Common StockPurchaseExcluded from purchase score | 2,000$17.08 / share | $34.16K | Mar 30Filed Apr 1 · 2d later | SEC filing |
$79,200 of common-equity purchase value after transaction-age decay across 180 days.
1 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.
At least one row increased reported same-security holdings by 10% or established a new reported position; indirect interests may overlap.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.
This reflects the filings imported so far, not a complete trading history.